Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Peloton Interactive Inc (PTON) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Peloton Interactive Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $303 (market cap $39.89B), while Peloton Interactive Inc trades at $5.83 (market cap $2.54B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 15.7× Peloton Interactive Inc's market cap, and Peloton Interactive Inc is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | PTON | |
|---|---|---|
Market Cap | $39.89B | $2.54B |
Sector | Health | Consumer Cyclical |
52-Week High | $491.22 | $9.00 |
52-Week Low | $278.09 | $3.71 |
Enterprise Value | $38.15B | $3.14B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Peloton Interactive (PTON) trades at $5.86, down 1.35% on the day, showing signs of stabilization after a 96% decline from pandemic highs. The company reported positive operating cash flow of $333M in 2025 and is projected to achieve profitability in 2026 with $23M net income. Technical indicators show a bullish moving average trend while fundamentals reveal improving margins and declining losses, though the stock carries a high P/E ratio of 97.83. Recent developments include inclusion in the S&P SmallCap 600 index and appointment of a new CFO.
PTON presents a turnaround opportunity with improving cash flow and projected profitability, but faces significant execution risks amid declining revenue and negative shareholder equity. Analyst consensus is cautiously optimistic with a $7.50 price target representing 28% upside, though the company must demonstrate sustainable subscriber growth to justify current valuations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Peloton Interactive Inc
Peloton Interactive Inc operates an interactive fitness platform. It operates its business in two reportable segments: Connected Fitness Products and Subscription. Connected Fitness Product revenue consists of sales of bike and tread and related accessories, associated fees for delivery and installation, and extended warranty agreements. Subscription revenue consists of revenue generated from monthly Connected Fitness Subscription and Digital Subscription. The company generates the majority of the revenue from the sale of Connected Fitness Products.
Read more on PTON →
